RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC - Seite 2
Phase 2 Data Summary in CPI-naïve NSCLC Patients (n=20)
PD-L1 Status | Confirmed Responses (n) | Confirmed ORR |
Positive (TPS ≥1%) | 8/20 | 40% |
Low (TPS 1-49%) | 6/16 | 38% |
High (TPS ≥50%) | 2/4 | 50% |
At the time of data cut off, there was one additional response among the PD-L1 low patients awaiting confirmation.
The combination of FLX475 and pembrolizumab was well tolerated in this Phase 2 NSCLC cohort. The most common treatment-emergent adverse event deemed related to study treatment was QT prolongation that was asymptomatic and reversible. FLX475 has now been dosed in more than 300 patients with various advanced cancers and has been generally well tolerated, and the combination with pembrolizumab has not increased immune-related toxicity beyond that expected with pembrolizumab alone.
In previous disclosures, FLX475 showed durable objective responses as monotherapy in an EBV+ lymphoma, as well as in combination with pembrolizumab in EBV+ gastric cancer.
Webcast Conference Call Information
RAPT will host a webcast conference call today, November 3, 2023 at 10:00 a.m. PT. To join the conference call via phone and participate in the live Q&A session, please pre-register online
here to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on
the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
Lesen Sie auch
About FLX475
FLX475 (tivumecirnon) is a small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues.
Treg represent a dominant pathway for downregulating the immune response, generally correlate with poor clinical outcomes, and may limit the effectiveness of currently available
therapies such as checkpoint inhibitors. FLX475 may restore naturally occurring antitumor immunity alone and may synergize with a variety of both conventional and immune-based therapies, such as
radiation, chemotherapy, checkpoint inhibitors, immune stimulators, cancer vaccines, and adoptive T cell therapy.